Trial Profile
PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms PLATINUM-China
- Sponsors Boston Scientific Corporation
- 27 Jan 2011 New trial record
- 26 Jan 2011 First patient enrolled, according to a Boston Scientific Corporation media release